Literature DB >> 34165715

Studying the Oncosuppressive Functions of PTENP1 as a ceRNA.

Glena Travis1, Nahal Haddadi1, Ann M Simpson1,2, Deborah J Marsh1,2,3, Eileen M McGowan1, Najah T Nassif4,5.   

Abstract

PTENP1 is a processed pseudogene of the tumour suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN). It functions posttranscriptionally to regulate PTEN by acting as a sponge for microRNAs that target PTEN. PTENP1 therefore functions as a competitive endogenous RNA (ceRNA), competing with PTEN for binding of microRNAs (miRNA) and thereby modulating PTEN cellular abundance. Studies of the overexpression of PTENP1 all confirm its oncosuppressive function to be mediated through the suppression of cell proliferation, induction of apoptosis, and inhibition of cell migration and invasion of cancer cells of differing types. These oncosuppressive functions are a direct consequence of miRNA binding by PTENP1 and the subsequent liberation of PTEN from miRNA induced suppression. In this chapter, we will focus initially on the description of a high efficiency transient transfection method to introduce and overexpress PTENP1 in the cell type of interest, followed by accurate methodologies to measure transfection efficiency by flow cytometry. We will then continue to describe two methods to analyze cell proliferation, namely the CCK-8 assay and Click-iT® EdU assay. Due to commonalities in the manifestation of the oncosuppressive effects of PTENP1, mediated through its role as a ceRNA, the methods presented in this chapter will have wide applicability to a variety of different cell types.

Entities:  

Keywords:  Cell proliferation; Overexpression; PTEN; PTENP1; Pseudogene; ceRNA

Year:  2021        PMID: 34165715     DOI: 10.1007/978-1-0716-1503-4_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  27 in total

1.  Posttranscriptional regulation of PTEN dosage by noncoding RNAs.

Authors:  Lin He
Journal:  Sci Signal       Date:  2010-11-02       Impact factor: 8.192

Review 2.  Pseudogenes: newly discovered players in human cancer.

Authors:  Laura Poliseno
Journal:  Sci Signal       Date:  2012-09-18       Impact factor: 8.192

Review 3.  Pseudogenes: pseudo or real functional elements?

Authors:  Wen Li; Wei Yang; Xiu-Jie Wang
Journal:  J Genet Genomics       Date:  2013-03-14       Impact factor: 4.275

4.  Subtle variations in Pten dose determine cancer susceptibility.

Authors:  Andrea Alimonti; Arkaitz Carracedo; John G Clohessy; Lloyd C Trotman; Caterina Nardella; Ainara Egia; Leonardo Salmena; Katia Sampieri; William J Haveman; Edi Brogi; Andrea L Richardson; Jiangwen Zhang; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

5.  A highly conserved processed PTEN pseudogene is located on chromosome band 9p21.

Authors:  P L Dahia; M G FitzGerald; X Zhang; D J Marsh; Z Zheng; T Pietsch; A von Deimling; F G Haluska; D A Haber; C Eng
Journal:  Oncogene       Date:  1998-05-07       Impact factor: 9.867

6.  A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells.

Authors:  Per Johnsson; Amanda Ackley; Linda Vidarsdottir; Weng-Onn Lui; Martin Corcoran; Dan Grandér; Kevin V Morris
Journal:  Nat Struct Mol Biol       Date:  2013-02-24       Impact factor: 15.369

7.  A coding-independent function of gene and pseudogene mRNAs regulates tumour biology.

Authors:  Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett Carver; William J Haveman; Pier Paolo Pandolfi
Journal:  Nature       Date:  2010-06-24       Impact factor: 49.962

8.  Molecular Evolution of PTEN Pseudogenes in Mammals.

Authors:  Jingsi Tang; Ruihong Ning; Bo Zeng; Ying Li
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

Review 9.  Pseudogenes regulate parental gene expression via ceRNA network.

Authors:  Yang An; Kendra L Furber; Shaoping Ji
Journal:  J Cell Mol Med       Date:  2016-08-25       Impact factor: 5.310

Review 10.  PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.

Authors:  Nahal Haddadi; Yiguang Lin; Glena Travis; Ann M Simpson; Najah T Nassif; Eileen M McGowan
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.